Roche axes Carmot obesity asset, 3 cancer drugs in R&D clear-out
Roche has axed one of the obesity assets from its $2.7 billion Carmot Therapeutics buyout, sending the molecule to…
Eye disease biotech launches with $100M, Roche rival in clinic
During his tenure at Roche’s Genentech, ophthalmologist Jason Ehrlich, M.D., Ph.D., supported the development of the blockbuster eye…
Roche’s Contivue Earns CE Mark for Continuous Eye Disease Treatment
Roche (OTCQX:RHHBY) has received CE mark approval for Contivue, its Port Delivery Platform…